Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01820325
Title Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Novartis|Novartis Pharmaceuticals
Indications

lung squamous cell carcinoma

Therapies

Buparlisib

Age Groups: adult
Covered Countries USA | ITA | ESP | DEU | CAN

Facility Status City State Zip Country Details
Highlands Oncology Group Fayetteville Arkansas 72703 United States Details
Northwest Cancer Specialists Compass Oncology -BKM Portland Oregon 97210 United States Details
Novartis Investigative Site Toronto Ontario M5G 1Z6 Canada Details
Novartis Investigative Site Ulm 89081 Germany Details
Novartis Investigative Site Napoli 80131 Italy Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Madrid 28046 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field